Trial Profile
An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Inotuzumab ozogamicin (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 24 Nov 2020 Results assessing efficacy of inotuzumab ozogamicin published in the Cancer
- 08 Dec 2018 Results (N=2743) of pooled analysis of three trials (NCT01564784,NCT01363297 and NCT00868608) published in the British Journal of Clinical Pharmacology
- 04 Dec 2018 Results (n=35) of two phase 1/2 (Study 1010) and phase 3 (Study 1022) studies assessing efficacy and safety of Inotuzumab Ozogamicin in patients with acute lymphoblastic leukemia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.